Market Overview

BIOLASE Wins FDA Clearance for 940nm Diolase 10 Diode Soft Tissue Laser

Related BIOL
Former Biolase CEO Announces Resignation From Biolase Board
Former CEO of Biolase Sends Letter To Correct Wrongful Allegations

BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, announced today that the U.S. Food and Drug Administration (FDA) has cleared the 940nm Diolase 10 diode soft tissue laser for use in 19 additional medical markets including: ear, nose and throat, oral surgery, arthroscopy, gastroenterology, general surgery, dermatology, plastic surgery, podiatry, GI/GU, gynecology, neurosurgery, ophthalmology, pulmonary surgery, cardiac surgery, thoracic surgery, urology, dermatology, aesthetics, and vascular surgery. This FDA clearance includes over 80 different procedures.

BIOLASE's diode lasers are used in dentistry for surgical soft tissue procedures as an alternative to invasive and traumatic conventional devices, such as the high-speed drill, scalpel or electrosurge. The 940nm wavelength is better absorbed by hemoglobin (Hb) and oxyhemoglobin (HbO2) than other diode laser wavelengths(1), so it cuts efficiently at low power and with considerably less heat and discomfort, making it an excellent alternative to conventional surgical devices. BIOLASE's 940nm wavelength is also FDA cleared for tooth whitening and temporary pain relief in a number of BIOLASE products.

Posted-In: News FDA

 

Related Articles (BIOL)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters